Listeria Rhomboencephalitis in a Patient on a Tumor Necrosis Factor a Inhibitor (Etanercept)

被引:5
|
作者
Mathews, Benji K. [1 ,2 ,3 ]
Chuang, Charles [4 ]
Rawal, Ajay [1 ,2 ,5 ]
Gertner, Elie [1 ,6 ]
机构
[1] Reg Hosp, St Paul, MN 55101 USA
[2] HealthPartners Med Grp & Clin, Bloomington, IN USA
[3] Univ Minnesota, Sch Med, Dept Med, St Paul, MN 55108 USA
[4] Minneapolis VA Med Ctr, Minneapolis, MN USA
[5] Univ Minnesota, Sch Med, St Paul, MN 55108 USA
[6] Univ Minnesota, Sch Med, Dept Internal Med, St Paul, MN 55108 USA
关键词
rhomboencephalitis; Listeria monocytogenes; rheumatoid arthritis; encephalopathy; BRAIN-STEM ENCEPHALITIS; CENTRAL-NERVOUS-SYSTEM; MONOCYTOGENES; RHOMBENCEPHALITIS; INFECTIONS; INFLIXIMAB; THERAPY; TNF;
D O I
10.1097/RHU.0000000000000151
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We describe a case of an 87-year-old woman with rheumatoid arthritis on etanercept who developed subacute encephalopathy. Magnetic resonance imaging and blood cultures led to the diagnosis of Listeria monocytogenes rhomboencephalitis, which proved to be fatal. Postmortem examination of the brain revealed abscesses with extensive necrosis. Gram stain showed small gram-positive rods in the necrotic tissue and the wall lining the abscesses. While rhomboencephalitis is a rare entity, and clinical recognition may be hampered by immunosuppression such as in this case, early blood cultures, lumbar puncture, and empiric treatment with ampicillin should be initiated in all patients with suspected rhomboencephalitis if suggested by imaging and by a clinical concern for infection.
引用
收藏
页码:325 / 327
页数:3
相关论文
共 50 条
  • [21] Subacute thyroiditis in a patient with psoriasis treated with a tumor necrosis factor-α inhibitor
    Wei, Yu-An
    Chuang, Wan-Chi
    Hong, Chien-Hui
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2018, 57 (07) : 869 - 871
  • [22] Systemic and spinal administration of etanercept, a tumor necrosis factor alpha inhibitor, blocks tactile allodynia in diabetic mice
    Ahmet Dogrul
    Husamettin Gul
    Ozgur Yesilyurt
    Umit H. Ulas
    Oguzhan Yildiz
    Acta Diabetologica, 2011, 48 : 135 - 142
  • [23] Systemic and spinal administration of etanercept, a tumor necrosis factor alpha inhibitor, blocks tactile allodynia in diabetic mice
    Dogrul, Ahmet
    Gul, Husamettin
    Yesilyurt, Ozgur
    Ulas, Umit H.
    Yildiz, Oguzhan
    ACTA DIABETOLOGICA, 2011, 48 (02) : 135 - 142
  • [24] Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor α antagonist etanercept
    Sacher, C
    Rubbert, A
    König, C
    Scharffetter-Kochanek, K
    Krieg, T
    Hunzelmann, N
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 46 (01) : 113 - 115
  • [25] Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor α antagonist etanercept
    Berookhim, B
    Fischer, HD
    Weinberg, JM
    CUTIS, 2004, 74 (04): : 245 - 247
  • [26] Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-α
    Mitoma, H
    Horiuchi, T
    Tsukamoto, H
    GASTROENTEROLOGY, 2004, 126 (03) : 934 - 935
  • [27] Etanercept: A novel tumor necrosis factor antagonist for the treatment of psoriatic disease
    Papp, Kim A.
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2007, 11 : S1 - S2
  • [28] Biologic therapy for psoriasis: The tumor necrosis factor inhibitors - Infliximab and etanercept
    Weinberg, JM
    CUTIS, 2003, 71 (01): : 25 - 29
  • [29] TUMOR NECROSIS FACTOR IS AN INHIBITOR OF ERYTHROPOIESIS INVIVO
    JOHNSON, RA
    WADDELOW, TA
    OLIFF, A
    ROODMAN, GD
    CLINICAL RESEARCH, 1988, 36 (03): : A412 - A412
  • [30] Serum tumor necrosis factor alpha increased during remission with Etanercept
    Mihaela Spirchez
    Gabriel Samasca
    Claudia Bolba
    Nicolae Miu
    Pediatric Rheumatology, 9 (Suppl 1)